Bioxytran (BIXT) Income from Continuing Operations (2010 - 2026)
Bioxytran (BIXT) posted Income from Continuing Operations of 2068989.0 for Q1 2026, down 296.24% sequentially from 522155.0 in Q4 2025, and down 52.85% YoY from 4387810.27 in Q1 2025.
Bioxytran (BIXT) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Bioxytran has reported Income from Continuing Operations for 17 years, with the latest figure at 2068989.0 in Q1 2026.
- Quarterly Income from Continuing Operations fell 52.85% year-over-year to 2068989.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 2838433.0 (up 10.17% YoY) and the FY2025 annual result came in at 2123077.0, up 10.8% from the prior year.
- Income from Continuing Operations declined to 2068989.0 in Q1 2026 per BIXT's latest filing, from 522155.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 35437.0 in Q2 2025 and troughed at 2068989.0 in Q1 2026.
- A 5-year average of 811844.94 and a median of 752138.0 in 2024 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2023 and 2025: Income from Continuing Operations tumbled 455.09% in 2023, then jumped 105.36% in 2025.
- Over 5 years, Income from Continuing Operations stood at 865932.0 in 2022, then sank by 35.02% to 1169170.0 in 2023, then jumped by 35.67% to 752138.0 in 2024, then surged by 30.58% to 522155.0 in 2025, then slumped by 296.24% to 2068989.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 2068989.0, 522155.0, and 282726.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 164.49 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -13.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 81.49 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -174.37 Mn |
| 10 | Bioxytran | 2.47 Mn | 2.22 Mn | - | -619,929.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.07 Mn |
| Dec 31, 2025 | -522,155.00 |
| Sep 30, 2025 | -282,726.00 |
| Jun 30, 2025 | 35,437.00 |
| Mar 31, 2025 | -1.35 Mn |
| Dec 31, 2024 | -752,138.00 |
| Sep 30, 2024 | -392,374.00 |
| Jun 30, 2024 | -661,647.00 |
| Mar 31, 2024 | -573,846.00 |
| Dec 31, 2023 | -1.17 Mn |
| Sep 30, 2023 | -1.13 Mn |
| Jun 30, 2023 | -1.45 Mn |
| Mar 31, 2023 | -817,977.00 |
| Dec 31, 2022 | -865,932.00 |
| Sep 30, 2022 | -203,149.00 |
| Jun 30, 2022 | -634,040.00 |
| Mar 31, 2022 | -963,386.00 |
| Dec 31, 2021 | -998,403.00 |
| Sep 30, 2021 | -609,682.00 |
| Jun 30, 2021 | -1.14 Mn |